1. Scrip
  2. >>Business
  3. >>Strategy

JDRF, PureTech Try Nonprofit Ownership To Fill Funding Gap

 
• By Alex Lash

Call it venture philanthropy with a twist: if all goes to plan, the Juvenile Diabetes Research Foundation will co-own a series of biotech companies dedicated to type 1 diabetes treatments without violating tax code, thanks to a structure created by Boston’s PureTech Ventures.

As venture firms flee early-stage risk and big drug companies slash research budgets, nonprofit disease foundations have tried to help turn biomedical discoveries into products, pitching in for industry research programs and drug trials. Now there’s a new twist: the high-profile and well-funded Juvenile Diabetes Research Foundation wants to build new companies.

The New York-based foundation is putting up to $5 million into ownership of a holding company dubbed T1D Innovations that...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Strategy

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By Kevin Grogan

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.

A Decade Of Transformation: Dong-A ST Readies For Take Off As An Innovative Pharma

 
• By Jung Won Shin

Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.

In Brief: Bavarian Nordic’s Board Votes For Private Equity Takeout

 
• By Joseph Haas

The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.

Novartis Signs Up For BioArctic Blood-Brain Barrier Tech

 
• By Kevin Grogan

The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.

More from Business

In Brief: Bavarian Nordic’s Board Votes For Private Equity Takeout

 
• By Joseph Haas

The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.

Novartis Signs Up For BioArctic Blood-Brain Barrier Tech

 
• By Kevin Grogan

The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.

Stock Watch: Bloodbaths And Blood Letting At CSL And Bayer

 
• By Andy Smith

Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.